The DKK1 Knockout MCF-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of MCF-7 cells carrying disruptive mutations in the DKK1 gene. This heterogeneous pool preserves genetic diversity while generating a functional DKK1 knockout background, avoiding clonal selection artifacts and enabling robust downstream analyses.
MCF-7 is an estrogen receptor (ER)- and progesterone receptor (PR)-positive human breast adenocarcinoma cell line derived from a pleural effusion of a patient with metastatic disease. It remains a principal model for hormone-responsive breast cancer due to its dependence on estrogen for proliferation and its well-characterized endocrine signaling pathways.
DKK1 encodes Dickkopf-1, a secreted glycoprotein that functions as a potent antagonist of the canonical Wnt/??-catenin pathway. Mechanistically, DKK1 simultaneously binds the Wnt co-receptors LRP5 and LRP6 along with the single-pass transmembrane proteins KREMEN1 and KREMEN2, promoting rapid endocytosis and clearance of the receptor complex from the plasma membrane. This sequestration prevents Wnt ligands from engaging Frizzled-LRP5/6 complexes, thereby blocking Dishevelled (DVL) recruitment and GSK3??-mediated phosphorylation events that normally stabilize ??-catenin. Consequently, ??-catenin is targeted for proteasomal degradation, and TCF/LEF-dependent transcription of growth-promoting genes such as MYC, CCND1, AXIN2, and LEF1 is suppressed. DKK1 is itself transcriptionally regulated by diverse factors, including TP53, estrogen/ER?? signaling, TGF-??, and the ??-catenin/TCF complex, placing it at a critical regulatory intersection of hormonal, tumor-suppressive, and developmental pathways.
In the MCF-7 breast cancer model, which typically maintains low basal Wnt pathway activity due to estrogen-driven suppression, DKK1 constitutes a critical negative regulator. CRISPR/Cas9-mediated disruption of DKK1 ablates this inhibitory brake, leading to elevated ??-catenin levels and transcription of downstream targets, thereby unmasking latent Wnt-driven phenotypes. This knockout system is thus invaluable for dissecting the molecular interplay between estrogen receptor and Wnt signaling cascades, as well as their collective influence on cancer stem cell traits, epithelial-to-mesenchymal transition, and the acquisition of invasive properties, particularly in the context of bone metastasis.
The DKK1 Knockout MCF-7 Polyclonal Cells enable detailed investigation of Wnt/??-catenin signaling dynamics in a hormone-responsive breast cancer background. Quantitative readouts such as TOP/FOP flash luciferase reporter assays, immunofluorescence for ??-catenin nuclear translocation, and RT-qPCR or RNA-seq profiling of classical Wnt targets (MYC, CCND1, AXIN2) are readily performed. The model also supports functional end-point analyses including transwell migration and invasion assays, flow cytometric cell cycle distribution, and MTT-based viability measurements under therapeutic challenge. Co-immunoprecipitation can validate disrupted DKK1 interaction with LRP6 or KREMEN1. These tools collectively facilitate research into estrogen-mediated regulation of Wnt activity, cancer stem cell maintenance, bone metastatic tropism, and mechanisms of endocrine therapy resistance. For additional technical details or ordering information, please contact Ascent Research.
